AR073218A1 - Anticuerpo antineuropilina 2 humano, induccion de la expresion del gen supresor de tumores p53 por la neutralizacion de la neuropilina 2 para el tratamiento de cancer - Google Patents

Anticuerpo antineuropilina 2 humano, induccion de la expresion del gen supresor de tumores p53 por la neutralizacion de la neuropilina 2 para el tratamiento de cancer

Info

Publication number
AR073218A1
AR073218A1 ARP090103308A ARP090103308A AR073218A1 AR 073218 A1 AR073218 A1 AR 073218A1 AR P090103308 A ARP090103308 A AR P090103308A AR P090103308 A ARP090103308 A AR P090103308A AR 073218 A1 AR073218 A1 AR 073218A1
Authority
AR
Argentina
Prior art keywords
human
neuropilin
expression
anthineuropiline
neutralization
Prior art date
Application number
ARP090103308A
Other languages
English (en)
Inventor
Christophe Borg
John Wijdenes
Camille Grand-Clement
Original Assignee
Diaclone
Efs Bourgogne France Comte
Univ Franche Comte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diaclone, Efs Bourgogne France Comte, Univ Franche Comte filed Critical Diaclone
Publication of AR073218A1 publication Critical patent/AR073218A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Además se divulga el uso de anticuerpos antineuropilina 2 humana o de ligandos de la neuropilina 2 humana derivados de esos anticuerpos, para la obtencion de un medicamento destinado a aumentar la expresion del p53 y a inducir la apoptosis de células tumorales, dentro del marco de un tratamiento anticanceroso. Reivindicacion 1: Un anticuerpo antineuropilina 2 humana, que se caracteriza porque su fijacion a las células tumorales que expresan la neuropilina 2 humana induce la apoptosis de las mencionadas células tumorales.
ARP090103308A 2008-08-27 2009-08-27 Anticuerpo antineuropilina 2 humano, induccion de la expresion del gen supresor de tumores p53 por la neutralizacion de la neuropilina 2 para el tratamiento de cancer AR073218A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0804725A FR2935385B1 (fr) 2008-08-27 2008-08-27 Induction de l'expression de p53 par neutralisation de la neuropiline-2 pour le traitement des cancers

Publications (1)

Publication Number Publication Date
AR073218A1 true AR073218A1 (es) 2010-10-20

Family

ID=40481948

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103308A AR073218A1 (es) 2008-08-27 2009-08-27 Anticuerpo antineuropilina 2 humano, induccion de la expresion del gen supresor de tumores p53 por la neutralizacion de la neuropilina 2 para el tratamiento de cancer

Country Status (10)

Country Link
US (1) US8722043B2 (es)
EP (1) EP2331576B1 (es)
JP (1) JP2012500832A (es)
CN (1) CN102498130A (es)
AR (1) AR073218A1 (es)
AU (1) AU2009286594A1 (es)
CA (1) CA2735169A1 (es)
FR (1) FR2935385B1 (es)
TW (1) TW201012476A (es)
WO (1) WO2010023382A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3460054B1 (en) 2013-03-15 2020-10-21 aTyr Pharma, Inc. Histidyl-trna synthetase-fc conjugates
US10040862B2 (en) 2014-04-18 2018-08-07 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to CD99
CN110536694A (zh) 2017-04-20 2019-12-03 Atyr 医药公司 用于治疗肺部炎症的组合物和方法
CN113226367A (zh) 2018-04-06 2021-08-06 Atyr 医药公司 包括抗nrp2抗体的组合物和方法
CN114746120B (zh) 2019-10-03 2024-07-30 Atyr医药公司 包含抗nrp2抗体的组合物和方法
CN111281968A (zh) * 2020-02-14 2020-06-16 杭州憶盛医疗科技有限公司 一种抗神经组织肿瘤药及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029729A2 (en) * 1997-12-09 1999-06-17 Children's Medical Center Corporation Antagonists of neuropilin receptor function and use thereof
EP1037981A1 (en) * 1997-12-09 2000-09-27 Children's Medical Center Corporation Soluble inhibitors of vascular endothelial growth factor and use thereof

Also Published As

Publication number Publication date
JP2012500832A (ja) 2012-01-12
CA2735169A1 (fr) 2010-03-04
FR2935385B1 (fr) 2013-04-19
US8722043B2 (en) 2014-05-13
AU2009286594A1 (en) 2010-03-04
CN102498130A (zh) 2012-06-13
WO2010023382A1 (fr) 2010-03-04
FR2935385A1 (fr) 2010-03-05
TW201012476A (en) 2010-04-01
EP2331576B1 (fr) 2014-07-16
US20120027779A1 (en) 2012-02-02
EP2331576A1 (fr) 2011-06-15

Similar Documents

Publication Publication Date Title
CL2016002359A1 (es) Anticuerpos que se une al receptor de crecimiento epidermal humano (anti-egfr) y conjugados de anticuerpo anti-egfr y fármaco
CL2019003266A1 (es) Anticuerpos anti-sirpalfa.
BR112019011450A2 (pt) células naturais killer modificadas e uso das mesmas
BR112015023333A8 (pt) pirrolbenzodiazepinas e conjugados dos mesmos
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
BR112012026213A8 (pt) Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
BR112018068678A2 (pt) anticorpos anti-mica
BR112014019861A2 (pt) anticorpo, ácido nucleico isolado, método de tratamento de um paciente com câncer, e, composição farmacêutica de um anticorpo
EA201691023A1 (ru) Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
TN2015000396A1 (en) Antibody drug conjugates
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
BR112015010740A2 (pt) Agentes para tratamento de doenças cancerosas expressando claudina
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
EA201890272A1 (ru) Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
CL2014003465A1 (es) Anticuerpo que se une al receptor del factor de crecimiento epidérmico humano dimérico (hegfr) ; composición farmacéutica que lo comprende; y uso para tratar el cáncer.
UY35399A (es) Conjugados de fármacos con anticuerpos
BR112015013127A2 (pt) imunoterapia com agentes de ligação
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
DOP2012000052A (es) Proteínas terapéuticas de unión a dll4
AR073218A1 (es) Anticuerpo antineuropilina 2 humano, induccion de la expresion del gen supresor de tumores p53 por la neutralizacion de la neuropilina 2 para el tratamiento de cancer
ECSP12011716A (es) (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer
AR068997A1 (es) Anticuerpos contra el vegf completamente humano y sus metodos de uso
EA032908B1 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
AR075982A1 (es) Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal